Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers, providing patients with precision treatment options, although effective, it is necessary to pay att···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：207
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positive tumors and opens up new hope for patients with advanced cancer.What diseases is Balversasuitable ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：230
Balversa is an innovative targeted therapy that effectively inhibits the growth of cancer cells for FGFR-positive tumors, bringing new treatment options to patients, but they need ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：204
Balversa, a new targeted anti-cancer drug, provides new treatment hope for patients with advanced cancer by precisely inhibiting the FGFR signaling pathway.Is Balversaexpensive? Ho···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：173
Balversa is a novel targeted anti-cancer drug that inhibits the FGFR signaling pathway for the treatment of advanced cancer, providing patients with precision treatment options and···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：126
Balversais an oral, targeted anti-cancer drug that specifically inhibits the FGFR signaling pathway and is used to treat specific types of advanced cancers, such as urothelial carc···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：178
Balversais an oral anticancer drug targeting FGFR mutations for the treatment of specific types of cancer, such as urothelial carcinoma, and provides patients with new therapeutic ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：237
Balversais a new oral anti-cancer drug targeting FGFR, which is specially designed for cancer patients with FGFR gene mutations, precisely inhibiting tumor growth, and providing ne···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：215
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell lung cancer and urothelial carcinoma, among others, and provides a new treatment option for patient···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：185
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2- advanced breast cancer, and the combination with fulvestrant further enhances the anti-tumor effec···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：189
Patients with HR/HER2- advanced breast cancer harboring PIK3CA mutations were significantly delayed in disease progression under the combination of Alpelisib and fulvestrant.What i···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：271
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic strategy for patients with HR/HER2- advanced breast cancer.What diseases can be treated with Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：188
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3172024-09-07
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：122025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：232025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：272025-27-11
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：3062025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：2712025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：3502024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：2492024-24-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
